Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 14/20 | 0.48 |
| ▸ | DRD4 | P21917 | 14/20 | 0.48 |
| ▸ | DRD3 | P35462 | 13/20 | 0.48 |
| ▸ | HSP90AA1 | P07900 | 5/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.45 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.45 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.45 |
| ▸ | HSP90AB1 | P08238 | 3/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14029806 | 0.89 | POLB (0.46) | DRD2DRD4DRD3HSP90AA1HSP90AB1 | |
| SCHEMBL5002722 | 0.85 | DRD2 (0.49) | DRD2DRD4DRD3OPRM1OPRK1 | |
| SCHEMBL5002719 | 0.82 | DRD2 (0.44) | DRD2DRD4DRD3OPRM1OPRK1 | |
| SCHEMBL501401 | 0.79 | PDK1 (0.45) | HSP90AA1HSP90AB1 | |
| SCHEMBL16827832 | 0.79 | DRD2 (0.53) | DRD2DRD4DRD3OPRM1OPRK1 | |
| SCHEMBL4999315 | 0.76 | HSP90AB1 (0.68) | HSP90AA1HSP90AB1 | |
| SCHEMBL14930035 | 0.75 | HSP90AB1 (0.58) | HSP90AA1HSP90AB1 | |
| SCHEMBL5002732 | 0.74 | HSP90AA1 (0.68) | HSP90AA1HSP90AB1 | |
| SCHEMBL27719349 | 0.73 | HSP90AA1 (0.44) | DRD2DRD4DRD3HSP90AA1OPRM1 | |
| SCHEMBL14029805 | 0.72 | POLB (0.43) | DRD2DRD4DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130116251-A1 | Novel HSP90 Inhibitor | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2013-05-09 | — | — | US | disclosed |
| US-20130116431-A1 | Novel HSP90 Inhibitor | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2013-05-09 | — | — | US | disclosed |
| US-20130116253-A1 | Novel HSP90 Inhibitor | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2013-05-09 | — | — | US | disclosed |
| US-20130116252-A1 | Novel HSP90 Inhibitor | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2013-05-09 | — | — | US | disclosed |
| EP-1857446-B1 | Derivatives of 3-(2,4-dihydroxyphenyl)-1,2,4-triazole useful in the treatment of cancer | NIPPON KAYAKU KK (JP) | 2013-05-01 | — | — | EP | disclosed |
| US-8399464-B2 | using a triazole compound; anticancer agent | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2013-03-19 | — | — | US | disclosed |
| US-20080269218-A1 | Novel Hsp90 Inhibitor | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2008-10-30 | — | — | US | disclosed |
| EP-1857446-A1 | NOVEL HSP90 INHIBITOR | Nippon Kayaku Kabushiki Kaisha (JP) | 2007-11-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130116252-A1 | Novel HSP90 Inhibitor | HSP90AB1, HSP90AB2P, HSP90B1 | DRD2 4421/4885DRD4 4661/4885DRD3 4025/4885 |
| US-20130116253-A1 | Novel HSP90 Inhibitor | HSP90AB1, HSP90AB2P, HSP90B1 | DRD2 4421/4885DRD4 4661/4885DRD3 4025/4885 |
| US-20080269218-A1 | Novel Hsp90 Inhibitor | HSP90AB1, HSP90AB2P, HSP90B1 | DRD2 4605/4885DRD4 4694/4885DRD3 4275/4885 |
| US-20130116251-A1 | Novel HSP90 Inhibitor | HSP90AB1, HSP90AB2P, HSP90B1 | DRD2 4421/4885DRD4 4661/4885DRD3 4025/4885 |
| US-20130116431-A1 | Novel HSP90 Inhibitor | HSP90AB1, HSP90AB2P, HSP90B1 | DRD2 4421/4885DRD4 4661/4885DRD3 4025/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.